"Cortex applauds Servier for their persistence in bringing this compound forward," said Dr. Varney. "This announcement is great news for both our companies and for the many patients who suffer from Alzheimer's disease and other neurodegenerative diseases."

Dr. Emmanuel Canet, head of Servier R&D commented, "Discovery of new therapeutic approaches for neurodegenerative disorders such as Alzheimer disease remains a major challenge and it is by joining forces through collaborations such as the one developed with Cortex, that we will be able to move forward to the clinic with innovative drugs for these diseases. S47445 fulfills all the criteria needed to enter clinical research and development as this High Impact AMPAKINE has demonstrated a compelling profile of activity in pre-clinical models. We now are looking forward to evaluating its clinical benefit in Alzheimer disease patients."

SOURCE Cortex Pharmaceuticals, Inc.